iRadimed Corporation (NASDAQ:IRMD) Receives Consensus Recommendation of “Buy” from Analysts

iRadimed Corporation (NASDAQ:IRMD) has earned a consensus rating of “Buy” from the five ratings firms that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, three have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $120.00.

A number of brokerages recently weighed in on IRMD. Weiss Ratings downgraded iRadimed from a “buy (b)” rating to a “buy (b-)” rating in a research report on Wednesday, May 20th. Freedom Capital raised iRadimed to a “strong-buy” rating in a research report on Thursday, April 2nd.

Insiders Place Their Bets

In related news, CEO Roger E. Susi sold 2,500 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $90.60, for a total transaction of $226,500.00. Following the sale, the chief executive officer owned 2,162,500 shares of the company’s stock, valued at $195,922,500. This trade represents a 0.12% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 55,000 shares of company stock worth $5,031,903 over the last 90 days. 34.60% of the stock is owned by company insiders.

Institutional Investors Weigh In On iRadimed

A number of institutional investors have recently added to or reduced their stakes in IRMD. Quarry LP bought a new stake in iRadimed during the third quarter valued at about $40,000. Farther Finance Advisors LLC boosted its position in iRadimed by 827.1% during the fourth quarter. Farther Finance Advisors LLC now owns 445 shares of the medical equipment provider’s stock valued at $43,000 after purchasing an additional 397 shares in the last quarter. Tower Research Capital LLC TRC raised its stake in iRadimed by 191.1% in the second quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock valued at $45,000 after buying an additional 495 shares during the last quarter. CWM LLC raised its stake in iRadimed by 19.5% in the fourth quarter. CWM LLC now owns 657 shares of the medical equipment provider’s stock valued at $64,000 after buying an additional 107 shares during the last quarter. Finally, USA Financial Formulas purchased a new stake in iRadimed in the fourth quarter valued at about $82,000. Institutional investors own 92.34% of the company’s stock.

iRadimed Stock Performance

IRMD opened at $92.20 on Friday. iRadimed has a 12-month low of $55.11 and a 12-month high of $107.90. The business’s fifty day simple moving average is $90.47 and its 200-day simple moving average is $95.85. The company has a market capitalization of $1.18 billion, a price-to-earnings ratio of 50.38 and a beta of 0.91.

iRadimed (NASDAQ:IRMD) last posted its quarterly earnings results on Friday, May 1st. The medical equipment provider reported $0.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.46 by $0.03. iRadimed had a return on equity of 24.48% and a net margin of 27.36%.The business had revenue of $21.98 million for the quarter, compared to the consensus estimate of $21.32 million. iRadimed has set its FY 2026 guidance at 2.060-2.210 EPS and its Q2 2026 guidance at 0.440-0.480 EPS. On average, equities research analysts predict that iRadimed will post 1.52 EPS for the current year.

iRadimed Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, May 29th. Investors of record on Friday, May 15th were given a dividend of $0.20 per share. The ex-dividend date of this dividend was Friday, May 15th. This represents a $0.80 dividend on an annualized basis and a yield of 0.9%. iRadimed’s dividend payout ratio (DPR) is presently 43.72%.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.